A nationwide clinical trial is investigating an experimental vaccine that, if successful, may halt the development of Alzheimer's disease, one of the more debilitating conditions afflicting the American public.
One of the 200 locations around the country for the trial is the Nathan Kline Institute for Psychiatric Research, a state-run center in New York that is currently looking for volunteers for the study, the Journal News reports.
The vaccine in question is called bapineuzumab, an antibody that may clear beta amyloid, which has been suspected in the past as a possible cause for Alzheimer's disease, according to the article.
Past research has tied the protein to memory loss and cognitive functioning.
"This is a radical new approach to the treatment of Alzheimer's disease. It actually treats the cause of the disease as opposed to treating just the symptoms," Nunzio Pomara, director at Nathan Kline, told the news provider.
Pomara added early results have shown bapineuzumab may help the body get rid of the beta amyloid protein before it causes the symptoms of Alzheimer's.
An estimated 5.2 million people in the U.S. are currently living with Alzheimer's disease. By 2030, it's estimated the number of individuals aged 65 and older with the disease will reach 7.7 million.